These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 15508049)
1. [Prevention of preterm delivery with gestagens]. Schindler AE Z Geburtshilfe Neonatol; 2004 Oct; 208(5):165-9. PubMed ID: 15508049 [TBL] [Abstract][Full Text] [Related]
2. Role of progestogens for the prevention of premature birth. Schindler AE J Steroid Biochem Mol Biol; 2005 Dec; 97(5):435-8. PubMed ID: 16198556 [TBL] [Abstract][Full Text] [Related]
3. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis. Odibo AO; Stamilio DM; Macones GA; Polsky D Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206 [TBL] [Abstract][Full Text] [Related]
4. Progesterone for preterm birth prevention: an evolving intervention. Tita AT; Rouse DJ Am J Obstet Gynecol; 2009 Mar; 200(3):219-24. PubMed ID: 19254577 [TBL] [Abstract][Full Text] [Related]
5. Use of progesterone to prevent preterm birth at a tertiary care center. Bailit JL; Berkowitz R; Thorp JM; Cleary K; Hartmann KE; Mercer BM J Reprod Med; 2007 Apr; 52(4):280-4. PubMed ID: 17506366 [TBL] [Abstract][Full Text] [Related]
6. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety. O'Brien JM; Lewis DF Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340 [TBL] [Abstract][Full Text] [Related]
8. 17 hydroxyprogesterone for the prevention of preterm delivery. Meis PJ; Obstet Gynecol; 2005 May; 105(5 Pt 1):1128-35. PubMed ID: 15863556 [TBL] [Abstract][Full Text] [Related]
9. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone? Hall NR Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799 [TBL] [Abstract][Full Text] [Related]
10. The use of progestational agents for preterm birth: lessons from a mouse model. Elovitz MA; Mrinalini C Am J Obstet Gynecol; 2006 Oct; 195(4):1004-10. PubMed ID: 17000233 [TBL] [Abstract][Full Text] [Related]
11. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. Spong CY; Meis PJ; Thom EA; Sibai B; Dombrowski MP; Moawad AH; Hauth JC; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S; Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1127-31. PubMed ID: 16157124 [TBL] [Abstract][Full Text] [Related]
12. Progesterone inhibits basal and TNF-alpha-induced apoptosis in fetal membranes: a novel mechanism to explain progesterone-mediated prevention of preterm birth. Luo G; Abrahams VM; Tadesse S; Funai EF; Hodgson EJ; Gao J; Norwitz ER Reprod Sci; 2010 Jun; 17(6):532-9. PubMed ID: 20360593 [TBL] [Abstract][Full Text] [Related]
13. Attitudes and practices regarding use of progesterone to prevent preterm births. Henderson ZT; Power ML; Berghella V; Lackritz EM; Schulkin J Am J Perinatol; 2009 Aug; 26(7):529-36. PubMed ID: 19301227 [TBL] [Abstract][Full Text] [Related]
14. From concept to practice: the recent history of preterm delivery prevention. Part II: Subclinical infection and hormonal effects. Vidaeff AC; Ramin SM Am J Perinatol; 2006 Feb; 23(2):75-84. PubMed ID: 16506112 [TBL] [Abstract][Full Text] [Related]
15. A survey of clinician and patient attitudes towards the use of progesterone for women at risk of preterm birth. Dodd JM; Ashwood P; Flenady V; Jenkins-Manning S; Cincotta R; Crowther CA Aust N Z J Obstet Gynaecol; 2007 Apr; 47(2):106-9. PubMed ID: 17355298 [TBL] [Abstract][Full Text] [Related]
16. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella Am J Obstet Gynecol; 2012 May; 206(5):376-86. PubMed ID: 22542113 [TBL] [Abstract][Full Text] [Related]
17. Cerclage, progesterone and α-hydroxyprogeterone caproate treatment in women at risk for preterm delivery. Haram K; Mortensen JH; Morrison JC J Matern Fetal Neonatal Med; 2014 Nov; 27(16):1710-5. PubMed ID: 24678618 [TBL] [Abstract][Full Text] [Related]
18. Increased incidence of gestational diabetes in women receiving prophylactic 17alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery. Rebarber A; Istwan NB; Russo-Stieglitz K; Cleary-Goldman J; Rhea DJ; Stanziano GJ; Saltzman DH Diabetes Care; 2007 Sep; 30(9):2277-80. PubMed ID: 17563346 [TBL] [Abstract][Full Text] [Related]
19. 17-alphahydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence? Barton JR; Barton LA; Istwan NB; Rhea DJ; Desch CN; Sibai BM Am J Obstet Gynecol; 2011 Sep; 205(3):269.e1-6. PubMed ID: 22071060 [TBL] [Abstract][Full Text] [Related]
20. Progestins for the prevention of spontaneous preterm birth: review and implications of recent studies. O'Brien JM; Lewis DF J Reprod Med; 2009 Feb; 54(2):73-87. PubMed ID: 19301570 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]